Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Repligen's annualizedGross Profit for the quarter that ended in Dec. 2024 was $155.4 Mil.
Repligen's average Total Assets over the quarter that ended in Dec. 2024 was $2,830.2 Mil. Therefore, Repligen's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 5.49%.
Repligen Gross-Profit-to-Asset % Historical Data
The historical data trend for Repligen's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Repligen's Gross-Profit-to-Asset %
For the Medical Instruments & Supplies subindustry, Repligen's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Repligen's Gross-Profit-to-Asset % falls into.
Repligen Gross-Profit-to-Asset % Calculation
Repligen's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Dec. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Repligen Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Repligen's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGEN has been successfully added to your 